Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs

Lancet. 2021 Mar 6;397(10277):878. doi: 10.1016/S0140-6736(21)00357-3. Epub 2021 Feb 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • COVID-19
  • COVID-19 Vaccines* / supply & distribution
  • Developing Countries*
  • Humans
  • Placebos
  • Randomized Controlled Trials as Topic / economics
  • Randomized Controlled Trials as Topic / ethics*
  • Risk Assessment
  • SARS-CoV-2
  • Therapeutic Equipoise

Substances

  • COVID-19 Vaccines
  • Placebos